Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM52HUD)

Drug Name

Dexloxiglumide Drug Info

Synonyms

Dexloxiglumide; 119817-90-2; (R)-4-(3,4-Dichlorobenzamido)-5-((3-methoxypropyl)(pentyl)amino)-5-oxopentanoic acid; UNII-69DY40RH9B; CR-2017; 69DY40RH9B; Dexloxiglumidum; Dexloxiglumida; Dexloxiglumide [INN]; Dexloxiglumidum [INN-Latin]; Dexloxiglumida [INN-Spanish]; PubChem16049; AC1Q3MXI; GTPL889; SCHEMBL366142; CHEMBL550781; AC1L24A8; DTXSID50152604; MolPort-006-170-001; CHEBI:135747; ZINC3801027; KS-000007QQ; AKOS000279054; PB12713; DB04856; CC-26372; AJ-45649; AK129760; AS-35102; KB-210163; AX8123879; CS-0054881; FT-0603098; Q-4119

Indication

Disease Entry	ICD 11	Status	REF
Pancreatic malfunction	DC30-DC3Z	Phase 2	[1]

Cross-matching ID

PubChem CID: 65937
ChEBI ID: CHEBI:135747
CAS Number: CAS 119817-90-2
TTD Drug ID: DM52HUD
INTEDE Drug ID: DR0470

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cholecystokinin receptor type A (CCKAR)	TTCG0AL	CCKAR_HUMAN	Inhibitor	[2]
Gastrin/cholecystokinin type B receptor (CCKBR)	TTVFO0U	GASR_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	Highest Status	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Phase 3	[4]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Phase 3	[4]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Phase 3	[4]
Cytochrome P450 2B6 (CYP2B6)	DEPKLMQ	CP2B6_HUMAN	Phase 3	[5]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Gastrin/cholecystokinin type B receptor (CCKBR)	DTT	CCKBR	5.618	5.638	5.466	6.002
Cholecystokinin receptor type A (CCKAR)	DTT	CCKAR	3.907	4.133	2.858	3.892
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	10.08	7.207	5.403	9.211
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	11.76	5.931	6.164	9.423
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	11.692	6.58	4.984	9.089

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Pancreatic malfunction

ICD Disease Classification

DC30-DC3Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Gastrin/cholecystokinin type B receptor (CCKBR)	DTT	CCKBR	6.53E-01	1.00E-03	4.05E-03
Cytochrome P450 2B6 (CYP2B6)	DME	CYP2B6	1.25E-01	-7.02E-02	-2.81E-01
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	9.83E-01	3.44E-02	7.14E-02
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	2.84E-06	1.24E-01	6.31E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.75E-01	3.78E-02	1.44E-01

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	Full agonists of CCK8 containing a nonhydrolyzable sulfated tyrosine residue. J Med Chem. 1989 Feb;32(2):445-9.
3	Synthesis and stereochemical structure-activity relationships of 1,3-dioxoperhydropyrido[1,2-c]pyrimidine derivatives: potent and selective cholecy... J Med Chem. 1997 Oct 10;40(21):3402-7.
4	Pharmacokinetic profile of dexloxiglumide. Clin Pharmacokinet. 2006;45(12):1177-88.
5	Effect of azole antifungals ketoconazole and fluconazole on the pharmacokinetics of dexloxiglumide. Br J Clin Pharmacol. 2005 Nov;60(5):498-507.